Clinical Trials Logo

Erythropoietin clinical trials

View clinical trials related to Erythropoietin.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05748561 Recruiting - Treatment Clinical Trials

Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial.

Start date: April 5, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this double-blind prospective randomized clinical trial is to determine if the effect of intravenous erythropoietin is superior to the effect of intravenous methylprednisolone in cases of toxic optic neuropathy 4 weeks after therapeutic intervention. The main question it aims to answer: • Is there a difference in the visual recovery of toxic optic neuropathies treated with intravenous methylprednisolone in comparison with those treated with intravenous erythropoietin?

NCT ID: NCT05683782 Recruiting - Erythropoietin Clinical Trials

Erythropoietin Gel as an Adjunct to Split-Thickness Apically Positioned Flap in Augmentation of Attached Gingiva

Start date: October 1, 2022
Phase: Phase 4
Study type: Interventional

This study will be carried out to evaluate the effect of topical application of erythropoietin gel as an adjunct to split-thickness apically positioned flap regarding Wound Healing and the Effect on post-surgical symptoms [ Patient Satisfaction] (1ry objective) and Clinical gain in width of attached gingiva. (2ry objective).

NCT ID: NCT05395195 Recruiting - Encephalopathy Clinical Trials

Erythropoietin for Neonatal Encephalopathy in LMIC (EMBRACE Trial)

EMBRACE
Start date: December 31, 2022
Phase: Phase 3
Study type: Interventional

One million babies die, and at least 2 million survive with lifelong disabilities following neonatal encephalopathy (NE) in low and middle-income countries (LMICs), every year. Cooling therapy in the context of modern tertiary intensive care improves outcome after NE in high-income countries. However, the uptake and applicability of cooling therapy in LMICs is poor, due to the lack of intensive care and transport facilities to initiate and administer the treatment within the six-hours window after birth as well as the absence of safety and efficacy data on hypothermia for moderate or severe NE. Erythropoietin (Epo) is a promising neuroprotectant with both acute effects (anti-inflammatory, anti-excitotoxic, antioxidant, and antiapoptotic) and regenerative effects (neurogenesis, angiogenesis, and oligodendrogenesis),which are essential for the repair of injury and normal neurodevelopment when used as a mono therapy in pre-clinical models (i.e without adjunct hypothermia). The preclinical data on combined use of Eythropoeitin and hypothermia is less convincing as the mechanisms overlap. Thus, the HEAL (High dose erythropoietin for asphyxia and encephalopathy) trial, a large phase III clinical trial involving 500 babies with with encephalopathy reported that that Erythropoietin along with hypothermia is not beneficial. In contrast, the pooled data from 5 small randomized clinical trials (RCTs) (n=348 babies), suggests that Epo (without cooling therapy) reduce the risk of death or disability at 3 months or more after NE (Risk Ratio 0.62 (95% CI 0.40 to 0.98). Hence, a definitive trial (phase III) for rigorous evaluation of the safety and efficacy of Epo monotherapy in LMIC is now warranted.

NCT ID: NCT04013646 Recruiting - Stroke Clinical Trials

Combination Therapy of Umbilical Cord Blood and Erythropoietin for Stroke Paients

Start date: May 2, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical trial is a clinical trial for the evaluation of the safety and efficacy of umbilical cord blood (UCB) therapy, UCB and erythropoietin (EPO) combination therapy in adult stroke patients.

NCT ID: NCT01131533 Recruiting - Pharmacokinetics Clinical Trials

Intraocular Pharmacokinetics of Erythropoietin After Single Intravitreal Injection in Human

Start date: January 2009
Phase: N/A
Study type: Interventional

The investigators investigate intraocular concentrations and pharmacokinetics of erythropoietin after a single intravitreal injection in humans.